Alexion augmenting pipeline with Zealand, Affibody deals

Alexion took a pair of steps toward further rebuilding its pipeline Wednesday, gaining rights to targets in the complement pathway via a deal with Zealand and adding a clinical-stage molecule from Affibody for IgG-mediated autoimmune diseases.

The deal with Zealand Pharma A/S

Read the full 413 word article

User Sign In